EPRX on Nasdaq
EUPRAXIA PHARMACEUTICALS INC.
Canadian pharmaceutical preparations company based in Victoria. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerEPRX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersVancouver, Canada2
- Incorporated inBritish Columbia, Canada4
- Business address2198 Yukon Street, Vancouver, V5Y 3P14
- Filer category, Emerging growth company4
- Legal formCorporation2
- LEI254900ABKL5YBZMSYH452
- StatusActive2
- LEI statusIssued and current2
- Registered address1500 Royal Centre, V6E 4N7 Vancouver, Canada2
- Registered withBC Registry Services, 8187173082
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-47.0%Return on equity3
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative | $17.1M | $10.9M |
| Research and development | $21.3M | $16.1M |
| Total expenses | $38.4M | $27.0M |
| Interest income | $1.4M | $1.2M |
| Interest expense | $0 | -$603.6K |
| Gain (loss) on sale of equipment | -$2.6K | $18.6K |
| Foreign exchange gain (loss) | -$1.6M | -$159.2K |
| Convertible debt costs | $0 | -$355.6K |
| Change in fair value of financial instruments | $0 | $1.2M |
| Total other income/(loss) | -$152.5K | $1.3M |
| Loss before tax expense | -$38.6M | -$25.7M |
| Tax expense | -$19.1K | -$1.8K |
| Owners of the Company | -$38.6M | -$25.5M |
| Non-controlling interest | -$29.5K | -$242.0K |
| Net loss for the year | -$38.6M | -$25.7M |
| Foreign currency translation adjustment | $2.1M | -$1.5M |
| Comprehensive loss for the year | -$36.5M | -$27.2M |
| Loss per share basic | -$1.03 | -$0.76 |
| Loss per share diluted | -$1.03 | -$0.76 |
| Weighted average shares outstanding basic | 40.0M shares | 33.9M shares |
| Weighted average shares outstanding diluted | 40.0M shares | 33.9M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $80.6M | $33.1M | |
| Prepaid expenses and deposits | $3.9M | $1.1M | |
| Amounts receivable | $674.2K | $228.9K | |
| Total current assets | $85.1M | $34.4M | |
| Prepaid expenses | $64.3K | $80.8K | |
| Property and equipment, net | $834.4K | $357.9K | |
| Right-of-use asset, net | $152.7K | $67.0K | $46.7K |
| Total assets | $86.2M | $34.9M | |
| Accounts payable and accrued liabilities | $5.5M | $3.0M | |
| Lease liability current portion | $78.5K | $71.9K | |
| Total current liabilities | $5.6M | $3.1M | |
| Lease liability | $75.9K | $0 | |
| Total liabilities | $5.7M | $3.1M | |
| Preferred Stock Value | $29.7M | $31.7M | |
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 51,939,206 (December 31, 2024 - 35,641,603 | $195.4M | $116.4M | |
| Additional paid-in capital | $28.5M | $20.5M | |
| Deficit | -$169.6M | -$131.0M | |
| Accumulated other comprehensive loss | -$2.0M | -$4.2M | |
| Equity attributable to the owners of the Company | $82.0M | $33.4M | |
| Non-controlling interest | -$1.6M | -$1.6M | |
| Total shareholders' equity | $80.4M | $31.8M | $892.3K |
| Total liabilities and shareholders' equity | $86.2M | $34.9M | |
| Common stock no par value | $0 | $0 | |
| Common stock shares issued | 51.9M shares | 35.6M shares | |
| Common stock shares outstanding | 51.9M shares | 35.6M shares | |
| Preferred Stock, Shares Issued | 8.4M shares | 8.9M shares | |
| Preferred Stock, Shares Outstanding | 8.4M shares | 8.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $80.6M | $33.1M | |
| Prepaid expenses and deposits | $3.9M | $1.1M | |
| Amounts receivable | $674.2K | $228.9K | |
| Total current assets | $85.1M | $34.4M | |
| Prepaid expenses | $64.3K | $80.8K | |
| Property and equipment, net | $834.4K | $357.9K | |
| Right-of-use asset, net | $152.7K | $67.0K | $46.7K |
| Total assets | $86.2M | $34.9M | |
| Accounts payable and accrued liabilities | $5.5M | $3.0M | |
| Lease liability current portion | $78.5K | $71.9K | |
| Total current liabilities | $5.6M | $3.1M | |
| Lease liability | $75.9K | $0 | |
| Total liabilities | $5.7M | $3.1M | |
| Preferred Stock Value | $29.7M | $31.7M | |
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 51,939,206 (December 31, 2024 - 35,641,603 | $195.4M | $116.4M | |
| Additional paid-in capital | $28.5M | $20.5M | |
| Deficit | -$169.6M | -$131.0M | |
| Accumulated other comprehensive loss | -$2.0M | -$4.2M | |
| Equity attributable to the owners of the Company | $82.0M | $33.4M | |
| Non-controlling interest | -$1.6M | -$1.6M | |
| Total shareholders' equity | $80.4M | $31.8M | $892.3K |
| Total liabilities and shareholders' equity | $86.2M | $34.9M | |
| Common stock no par value | $0 | $0 | |
| Common stock shares issued | 51.9M shares | 35.6M shares | |
| Common stock shares outstanding | 51.9M shares | 35.6M shares | |
| Preferred Stock, Shares Issued | 8.4M shares | 8.9M shares | |
| Preferred Stock, Shares Outstanding | 8.4M shares | 8.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$38.6M | -$25.7M |
| Accrued interest on convertible debt | $241.6K | |
| Depreciation | $237.7K | $171.7K |
| Interest lease liability | $6.7K | $6.7K |
| Third-party service costs settled in equity | $281.7K | |
| Loss (gain) on sale of equipment | $2.6K | -$18.6K |
| Share-based payments | $8.8M | $3.2M |
| Change in fair value of financial instruments | $0 | -$1.2M |
| Lease payments | -$83.7K | -$65.7K |
| Unrealized foreign exchange | $1.6M | $156.1K |
| Accounts payable and accrued liabilities | $2.4M | -$714.9K |
| Payable to Auritec | -$5.0M | |
| Prepaid expenses | -$2.6M | -$948.4K |
| Amounts receivable | -$431.4K | -$101.4K |
| Cash used in operating activities | -$28.6M | -$30.0M |
| Acquisition of equipment | -$588.9K | -$104.2K |
| Proceeds from sale of equipment | $29.1K | |
| Cash used in investing activities | -$588.9K | -$75.2K |
| Overnight marketed public offering (net of transaction costs) | $73.9M | $22.9M |
| Non-brokered private placement (net of transaction costs) | $31.7M | |
| Redemption of warrants | $1.5M | $337.8K |
| Redemption of options | $639.6K | $25.2K |
| Repayment of loans | -$62.7K | |
| Repayment of convertible debt | -$9.1M | |
| Cash provided by financing activities | $76.1M | $45.8M |
| Increase in cash | $46.9M | $15.7M |
| Foreign exchange effect on cash | $544.8K | -$2.0M |
No quarter-by-quarter statement was filed.
Leadership
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Executive OfficerAmanda Malone named Aug 22, 2023 to Nov 8, 20247
- Executive OfficerBruce Cousins named Aug 22, 2023 to Nov 8, 20247
- Executive Officer, DirectorJames Helliwell named Aug 22, 2023 to Nov 8, 20247
- Executive OfficerMark Kowalski named Aug 22, 2023 to Nov 8, 20247
- Executive OfficerPaul Brennan named Aug 22, 2023 to Nov 8, 20247
- Executive OfficerRahul Sarugaser named Nov 8, 20247
- DirectorJohn Montalbano named Aug 22, 2023 to Nov 8, 20247
- DirectorJoseph Freedman named Nov 8, 20247
- DirectorMichael Wilmink named Aug 22, 2023 to Nov 8, 20247
- DirectorPaul Geyer named Aug 22, 2023 to Nov 8, 20247
- DirectorRichard Glickman named Aug 22, 2023 to Nov 8, 20247
- DirectorSimon Pimstone named Aug 22, 2023 to Nov 8, 20247
Timeline
- May 11, 2012Founded EUPRAXIA PHARMACEUTICALS INC. is founded2
Filings
119 filings to the SEC since October 2021: 3 annual reports, 10 large holders, 2 private raises, 104 other. The latest 20:
- Oct 15, 20266-K EDGAR
- Oct 9, 20266-K EDGAR
- Sep 30, 20266-K EDGAR
- Sep 8, 20266-K EDGAR
- Sep 2, 2026SUPPL EDGAR
- Aug 24, 2026EFFECT EDGAR
- Aug 19, 2026F-10/A EDGAR
- Aug 13, 20266-K EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 20266-K EDGAR
- Aug 6, 2026F-X EDGAR
- Aug 6, 2026F-10 EDGAR
- Jul 15, 20266-K EDGAR
- Jul 13, 20266-K EDGAR
- Jul 7, 20266-K EDGAR
- Jun 22, 20266-K EDGAR
- May 29, 20266-K EDGAR
- May 29, 20266-K EDGAR
- May 28, 20266-K EDGAR
- May 12, 20266-K EDGAR
The 119 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- MANCHESTER MANAGEMENT CO LLCSCHEDULE 13G/A, 4 filings Nov 13, 2025 to Aug 13, 20268
- Joseph S. FreedmanSCHEDULE 13D/A, 3 filings Nov 7, 2024 to Mar 16, 20269
- Beutel, Goodman & Co Ltd.SCHEDULE 13G, 1 filing Nov 14, 202510
- Robert DisbrowSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Nov 14, 202511
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 68. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 1,650,000 | $10.9M | 0.5% | +60,995 |
| Balyasny Asset Management L.P. | 1,350,015 | $8.9M | 0.0% | +15 |
| Vivo Capital, LLC | 1,350,000 | $8.9M | 0.8% | No change |
| Scotia Capital Inc. | 1,343,726 | $8.8M | 0.0% | +1,548 |
| PFM Health Sciences, LP | 1,210,661 | $8.0M | 0.7% | +669,790 |
| Great Point Partners LLC | 1,200,000 | $7.9M | 1.9% | No change |
| Jupiter Topco LLC | 1,046,000 | $6.9M | 0.0% | New |
| Rubric Capital Management LP | 867,424 | $5.7M | 0.1% | +176,254 |
| Ikarian Capital, LLC | 809,741 | $5.4M | 0.9% | −405,000 |
| Woodline Partners LP | 746,864 | $4.9M | 0.0% | +306,313 |
| Point72 Asset Management, L.P. | 730,284 | $4.8M | 0.0% | −237,291 |
| Ameriprise Financial Inc | 711,024 | $4.7M | 0.0% | +61,950 |
| Redmile Group, LLC | 611,400 | $4.0M | 0.3% | −88,600 |
| Seven Fleet Capital Management LP | 610,785 | $4.0M | 0.7% | +177,270 |
| UBS Group AG | 519,211 | $3.4M | 0.0% | −243,424 |
| Citadel Advisors LLC | 502,011 | $3.3M | 0.0% | +271,835 |
| Millennium Management LLC | 441,586 | $2.9M | 0.0% | New |
| Alyeska Investment Group, L.P. | 375,000 | $2.5M | 0.0% | No change |
| Picton Mahoney Asset Management | 360,878 | $2.4M | 0.0% | New |
| Velan Capital Investment Management LP | 352,000 | $2.3M | 1.4% | No change |
| Jane Street Group, LLC | 329,053 | $2.2M | 0.0% | +293,843 |
| Aisling Capital Management LP | 325,000 | $2.1M | 0.5% | No change |
| SummitTX Capital, L.P. | 318,784 | $2.1M | 0.1% | −9,213 |
| Royal Bank Of Canada | 311,435 | $2.1M | 0.0% | +50,059 |
| Dv Equities, LLC | 276,000 | $1.8M | 0.3% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11